Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 2 M8 D/ j9 W/ v' f
6 c1 r3 t" r) {* u6 x% h& ]$ a* G+ j* C
Sub-category:
, |" G% O2 t& G8 V' p: b- AMolecular Targets k0 \, ~, g, L" J; |4 O n
2 Y( t& C" y9 u! k& |# `
8 n, \8 \6 M& y/ A" SCategory:! k. L9 m( F6 B3 q* A
Tumor Biology
1 F7 j- c8 ^5 i% U+ d1 |! D5 e& |* e! d0 m
! `! [& r% m/ v- A% MMeeting:8 y% i, {; X# ]$ V; P
2011 ASCO Annual Meeting
# [0 T8 X- F! h# M: ^ R5 [5 J) \+ h( X( v2 Y
. o& H8 B5 }% ]! {* F- [" S* f9 ^Session Type and Session Title:
, x- r& ]/ o8 e8 _- ~3 `( JPoster Discussion Session, Tumor Biology
9 {* q+ M3 I+ l: |3 J" r( T
) O- t- c5 T) ~8 f" Q* a y1 I" {, j# Z3 z
Abstract No:
, j. [5 n$ e8 b8 y( ?4 l& N0 W9 Y5 k10517
3 _1 M0 n# H4 h: N9 c
7 X( c M$ p7 y
6 T9 T' ]: P9 W* |, t" B3 r! \8 |Citation:
/ M6 j4 s O, M: g8 p; y0 hJ Clin Oncol 29: 2011 (suppl; abstr 10517) ! o3 ~$ P" ~; q: _4 e9 ^4 u: V
2 z# P! }$ ^+ ]
. w8 [; N, z lAuthor(s):
! \0 {1 q7 ~! u( @: e- @8 v3 vJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) c9 b, B$ A# n" J
$ K$ \& A2 Z W* g
+ h' {" I4 d2 |9 X4 G5 T
; | p4 K$ J% ^7 H, w) ^- R7 W. c" cAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.% Q% O' A1 [! i J b H3 T1 j
/ `! f2 z+ B U: B
Abstract Disclosures, e! x! R+ Z$ U6 N8 I# J, h V9 C- j
! a; m2 [" n1 @. tAbstract:
- H+ V- D! w9 x2 l
# w- n1 j3 F6 _% a% `; v$ \; A5 X) C" g/ Q. n
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.+ O9 p( z6 Z5 k9 n) q" Q) G
# g+ i. R* g. ^
; H5 h; \2 g6 z9 c
|
, x; @/ p/ j/ d% ]1 \ d
显身卡
